How to appeal a Blue Cross Blue Shield of Michigan continuous glucose monitors & insulin pumps denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Blue Cross Blue Shield of Michigan-specific note: Largest insurer in Michigan (~4.5M members). Statutory non-profit mutual. Switched PBM from Express Scripts to OptumRx effective January 2024 — appeals around 2024-2025 may involve formulary disruption. Michigan DIFS oversight.

What Blue Cross Blue Shield of Michigan's policy requires for continuous glucose monitors & insulin pumps

Cited policy: BCBS Medical Policy - External Insulin Pump / Hybrid Closed-Loop

T1DM or insulin-requiring T2DM (with C-peptide); AID systems covered when FDA-cleared.

How Blue Cross Blue Shield of Michigan denies continuous glucose monitors & insulin pumps — and how to counter it

Where Blue Cross Blue Shield of Michigan pushes back: 1) 'Try MiniMed 670G or 770G before 780G'; 2) 'SmartGuard auto-bolus too aggressive'; 3) 'No clinical advantage over predicate'.

Counter-arguments that hold up: MiniMed 770G has been discontinued by Medtronic; 670G is two generations old. 780G + Guardian 4 FDA-approved Apr 21, 2023 with meal-detection auto-correction every 5 min — first AID with this feature. ADAPT (Choudhary P et al., Lancet Diabetes Endocrinol 2022;10:720-731): 1.4% A1c reduction and 27.6% TIR improvement vs MDI+isCGM at 6 months, sustained at 12 months, no DKA or severe hypo. Auto-correction is the mechanism of benefit, not a safety risk.

What Blue Cross Blue Shield of Michigan typically denies for continuous glucose monitors & insulin pumps

Across Blue Cross Blue Shield of Michigan's commercial and Medicare books, denials cluster around a small number of patterns. For continuous glucose monitors & insulin pumps, expect:

• Step therapy via OptumRx (PBM since 2024)
• Site-of-care reductions for infusions
• Behavioral health prior auth
• OON balance bill disputes

Treatments most often denied in this category

These are the continuous glucose monitors & insulin pumps treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Dexcom G7
• Dexcom G6
• Libre 3 Plus
• Libre 2 Plus
• Eversense 365
• Tandem t:slim X2

How to submit the appeal to Blue Cross Blue Shield of Michigan

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Blue Cross Blue Shield of Michigan cited in the denial.
3. File the appeal through Blue Cross Blue Shield of Michigan's portal (members: https://www.bcbsm.com ; providers: https://providers.bcbsm.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MI, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Blue Cross Blue Shield of Michigan's prior-authorization criteria by drug: Blue Cross Blue Shield of Michigan PA criteria on ApprovalHelp.